Physician profile
Sumit Bhutani
NPI 1932347820
$3,144.52
in general payments reported to CMS, 2019-2025
14 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $160 · 2021: $758 · 2022: $664 · 2023: $659 · 2024: $163 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $973.65 | 2019-2025 | Arikayce |
| Gilead Sciences, INC. | $646.46 | 2019-2025 | Biktarvy, Veklury |
| Paratek Pharmaceuticals, INC. | $346.55 | 2021-2024 | Nuzyra |
| Abbvie INC. | $269.26 | 2021-2025 | Dalvance |
| Merck Sharp & Dohme LLC | $222.32 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Melinta Therapeutics, LLC | $175.22 | 2019-2025 | Rezzayo, Kimyrsa |
| Viiv Healthcare Company | $125.31 | 2021-2025 | Cabenuva, Dovato |
| Glaxosmithkline, LLC. | $110.43 | 2023 | |
| Mylan Specialty L.P. | $110.00 | 2019 | |
| Allergan, INC. | $57.18 | 2019-2020 | |
| Shionogi INC | $47.81 | 2022-2024 | Fetroja |
| Smith+Nephew, INC. | $28.01 | 2022-2025 | Collagenase Santyl |
| Aimmune Therapeutics, INC. | $19.96 | 2025 | Vowst |
| Polarityte, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Bhutani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.